Faculty & Staff Details
|Name:||Ronald Hall, Pharm.D., M.S.C.S., BCPS|
|Position:||Associate Professor, Clinical Research & Sciences Division, Dallas SW|
|Bio||Dr. Hall is an Associate Professor of Pharmacy Practice at the Texas Tech University HSC School of Pharmacy. He was selected in 2006 by National Institutes of Health (NIH) to be one of 14 Clinical Research Scholars. This three-year program at the University of Texas Southwestern Medical Center is designed to help the NIH cultivate independent clinical researchers who are capable of becoming the next generation of leaders in patient-oriented research.|
1999 St. Louis College of Pharmacy, St. Louis, Missouri: B.S. in Pharmacy
2000 St. Louis College of Pharmacy, St. Louis, Missouri: Doctor of Pharmacy
2001 Baptist Memorial Health Care, Memphis, Tennessee: Pharmacy Practice Residency
2002 South Texas Veterans Healthcare System, San Antonio, Texas: Infectious Diseases Specialty Residency
2009 University of Texas Southwestern, Dallas, Texas: Masters of Science in Clinical Sciences with distinction
Honors and Awards:
2008 Young Alumni of the Year, St. Louis College of Pharmacy
2007 2006 Texas Tech University HSC, School of Pharmacy - P2 Teaching Team of the Year (Infectious Diseases)
Dr. Hall has served many professional organizations including the American College of Clinical Pharmacy, American Society for Microbiology, and Infectious Diseases Society of America, and Society of Infectious Diseases Pharmacists. He serves as a reviewer for several professional journals including Clinical Infectious Diseases.
Dr. Hall serves as the program director for the Dose Optimization and Outcomes Research (DOOR) program. The primary research focus of the DOOR program is evaluating pharmacokinetics and pharmacodynamics of pharmaceutical agents in obese patients to provide optimal medication dosing for these patients.
Select Research Publications (* = corresponding author):
1. Busti AJ, Bain AM, Hall RG, Bedimo RG, Leff RD, Meek C, Mehvar R. Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin. J Cardiovasc Pharmacol 2008;51(6):605-10. PMID: 18520949
2. *Hall RG, Payne KD, Bain AM, Rahman AP, Nguyen ST, Eaton SA, Busti AJ, Vu SL, Bedimo R. Multicenter evaluation of vancomycin dosing – emphasis on obesity. Am J Med 2008;121:515-8. PMID: 18501233
3. Burgess DS, Hall RG. Simulated comparison of ciprofloxacin and levofloxacin pharmacodynamics against Pseudomonas aeruginosa using healthy volunteer pharmacokinetic and 2002 minimum inhibitory concentration (MIC) data. Clin Ther 2007;29(7):1421-7. PMID: 17825693
4. Burgess DS, Hall RG. In vitro activity of parenteral ?-lactams, levofloxacin and tobramycin alone or in combination against extended-spectrum ?-lactamase producing Klebsiella pneumoniae. Int J Antimicrob Agents 2004;24:48-52. PMID: 15225861
5. Burgess DS, Hall RG. In vitro activity of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae. Diagn Microbiol Infect Dis 2004;49(1):41-6. PMID: 15135499
6. Burgess DS, Hall RG, Lewis JS, Jorgensen JH, Patterson JE. Outcomes of patients infected with extended-spectrum beta-lactamase (ESBL) producing bacteria at a university hospital. Pharmacotherapy 2003;23(10):1232-7. PMID: 14594340
7. Burgess DS, Hall RG, Hardin TC. In vitro evaluation of the activity of two doses of levofloxacin alone and in combination with other agents against Pseudomonas aeruginosa. Diagn Microbiol Infect Dis 2003;46(2):131-7. PMID: 12812717
Research Abstracts for 2009-2010:
1. Hazelwood K, Brouse SD, Giuliano C, Alvarez C, Frei CR, Forcade N, Haase KK, Bedimo R, Bell T, Hall RG. A multi-center study evaluating the impact of IDSA guideline-recommended empiric dosing on nephrotoxicity. Presented by K. Hazelwood at the Infectious Diseases Society of America Meeting, Vancouver, Canada, 10/10.
2. Giuliano C, Haase K, Hazelwood K, Alvarez C, Frei C, Forcade N, Brouse S, Bell T, Bedimo R, Hall R. A multi-center study evaluating the impact of guideline-recommended empiric dosing of vancomycin in MRSA bacteremia. Presented by C. Giuliano at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Boston, Massachusetts, 9/10.
3. Hall RG, Meek C, Swancutt M, Leff R, Gubmo T. A surprising effect of weight on ethambutol (EMB) pharmacokinetics (PK). Presented by R. Hall at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Boston, Massachusetts, 9/10.
4. Anderson G, Hall R, Stoll J, Nelson AA. Comparison of OSCE absolute criteria reliability established using the Angoff and borderline group regression procedures. Presented by G. Anderson at the American Association of Colleges of Pharmacy Annual Meeting. Seattle, Washington, 7/10.
5. Gressett S, Lopes-Serrao M, Hall R, Shah S. An evaluation of myelosuppression in obese patients with a capped BSA. J Oncol Pharm Practice. 2010;16(S1):abst# P2.
6. Forcade NA, Hall RG, Brouse SD, Giuliano C, Hazelwood K, Krystal Haase K, Frei CR. Comparison of health outcomes and nephrotoxicity for diabetic and non-diabetic patients hospitalized for MRSA bacteremia. Fifth Decennial International Conference on Healthcare-Associated Infections. Atlanta, GA, 3/10.
7. Hazlewood KA, Hall RG, Brouse SD, Duquaine SM, Bedimo R. Effect of guideline recommended vancomycin dosing on nephrotoxicity rates in patients with MRSA bacteremia (Abstract #956). Presented to K. Hazlewood at the Society of Critical Care Medicine’s 39th Critical Care Congress. Miami, Florida, 1/10.
8. Pasipanodya J, Hall R, Weis S, Gumbo T. Fat, fractals, and failure of antituberculosis pharmacotherapy (Abstract #L1-1660). Presented by T. Gumbo at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA, 9/09.
Select Reviews and Book Chapters (* = corresponding author):
1. *Arnold A, Brouse SD, Pitcher WD, Hall RG. Empiric therapy for gram-negative pathogens in nosocomial and health-care associated pneumonia: Starting with the end in mind. J Int Care Med 2010 (in press).
2. *Hazlewood KA, Brouse SD, Pitcher WD, Hall RG. Vancomycin-associated nephrotoxicity: Grave concern or death by character assassination? Am J Med 2010;123:182.e1-182.e7.
3. Pasipanodya J, Hall R, Gumbo T. Tuberculosis and Other Mycobacterial Diseases. In: Bope ET, Rakel RE, Kellerman R, eds. Conn’s Current Therapy 2010. Philadelphia, PA: Elsevier Inc.; 2010;299-305.
4. *Giuliano C, Haase KK, Hall R. Use of vancomycin pharmacokinetic-pharmacodynamic properties in the treatment of MRSA infections. Expert Review of Infect Dis 2010;8(1):95-106.
5. *Hall RG, Leff RD, Gumbo T. Treatment of active pulmonary tuberculosis in adults: Current standards and recent advances: Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2009;29(12): 1468-81.
6. *Hall RG, Foslein-Nash C, Singh DK, Zeiss RA, Sanders KM, Patry R, Leff R. A formalized teaching, practice, and research partnership with the Veterans Affairs North Texas Health Care System: A model for advancing academic practice partnerships. Am J Pharm Educ 2009;73(8) Article 141.
7. *Hall RG. Nosocomial Pneumonia. In: Cheng JWM, Chessman KH, Hume AL et al., eds. Pharmacotherapy Self-Assessment Program, 6th ed. Infectious Diseases Module. Lenexa, KS: American College of Clinical Pharmacy;2008:109-26.
8. *Maclayton DO, Hall RG. Pharmacologic options for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) nosocomial pneumonia. Ann Pharmacother 2007;41:235-44. PMID: 17299012.
9. Burgess DS & Hall RG. Aztreonam. In: Yu VL, Edwards G, McKinnon PS, Peloquin C, Morse GD, eds. Antimicrobial Therapy and Vaccines. 2nd ed. Pitts